Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$542.52-1.4%$544.44$476.49▼$1,211.20$58.57B0.33929,805 shs1.31 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals0.00%-4.44%+5.63%-3.67%-50.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationREGNRegeneron Pharmaceuticals4.8256 of 5 stars4.43.01.72.32.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceREGNRegeneron Pharmaceuticals 2.80Moderate Buy$814.5750.14% UpsideCurrent Analyst Ratings BreakdownLatest REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$560.00 ➝ $584.007/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$755.00 ➝ $754.006/30/2025REGNRegeneron PharmaceuticalsArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/9/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.006/5/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.006/2/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$700.00 ➝ $650.006/2/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.006/2/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.005/30/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$662.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookREGNRegeneron Pharmaceuticals$14.20B4.12$45.71 per share11.87$268.50 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateREGNRegeneron Pharmaceuticals$4.41B$39.2813.8114.272.0131.94%15.27%11.93%8/1/2025 (Estimated)Latest REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.53N/AN/AN/A$3.30 billionN/A4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthREGNRegeneron Pharmaceuticals$3.520.65%N/A8.96%N/ALatest REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioREGNRegeneron Pharmaceuticals0.094.934.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipREGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipREGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableREGNRegeneron Pharmaceuticals15,106107.96 million100.39 millionOptionableREGN HeadlinesRecent News About These CompaniesAustralianSuper Pty Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)1 hour ago | marketbeat.comMassachusetts Financial Services Co. MA Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)3 hours ago | marketbeat.comBalentine LLC Invests $680,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 9:18 AM | marketbeat.comVictory Capital Management Inc. Sells 42,722 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 6:15 AM | marketbeat.comEdgestream Partners L.P. Sells 6,573 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 5:18 AM | marketbeat.comCwm LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 19 at 4:45 AM | marketbeat.comRegeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer?July 18 at 12:57 PM | tipranks.comRegeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?July 18 at 10:56 AM | zacks.comEvergreen Wealth Management LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 18 at 10:26 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bailard Inc.July 18 at 8:41 AM | marketbeat.comWealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 18 at 5:58 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Concord Wealth PartnersJuly 17 at 8:10 AM | marketbeat.comCullen Frost Bankers Inc. Has $4.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 17 at 7:13 AM | marketbeat.comUBS Raises Regeneron (REGN) Price Target, Maintains Neutral RatingJuly 16, 2025 | msn.comRegeneron Advances Melanoma Treatment with New Phase 2 TrialJuly 16, 2025 | tipranks.comRegeneron’s Innovative Approach in Follicular Lymphoma Treatment: A New Phase 3 TrialJuly 16, 2025 | tipranks.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Grandfield & Dodd LLCJuly 16, 2025 | marketbeat.comApollon Wealth Management LLC Has $2.22 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 16, 2025 | marketbeat.com1 Healthcare Stock on Our Buy List and 2 to Brush OffJuly 15, 2025 | finance.yahoo.comCenterBook Partners LP Sells 10,270 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15, 2025 | marketbeat.comConcord Asset Management LLC VA Has $1.33 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN Company DescriptionsRegeneron Pharmaceuticals NASDAQ:REGN$542.52 -7.48 (-1.36%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$545.00 +2.49 (+0.46%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
